Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma

PLoS ONE - United States
doi 10.1371/journal.pone.0082742
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

An Introduction to Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Human Cancer

American Journal of Hematology
Hematology
2019English

Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy

JAMA Oncology
Cancer ResearchOncology
2018English

Prospects to Improve Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors

Immunotherapy
OncologyAllergyImmunology
2016English

Chimeric Antigen Receptor T-Cell Immunotherapy for Glioblastoma: Practical Insights for Neurosurgeons

Neurosurgical Focus
MedicineSurgeryNeurology
2018English

Chimeric Antigen Receptor T Cells for the Treatment of Lymphoma

Annals of Lymphoma
2017English

Chimeric Antigen Receptor T Cell Targeting B Cell Maturation Antigen Immunotherapy Is Promising for Multiple Myeloma

Annals of Hematology
MedicineHematology
2019English

Targeting the Adenosine 2A Receptor Enhances Chimeric Antigen Receptor T Cell Efficacy

Journal of Clinical Investigation
Medicine
2017English

Design and Implementation of Adoptive Therapy With Chimeric Antigen Receptor-Modified T Cells

Immunological Reviews
AllergyImmunology
2013English

Chimeric Antigen Receptors for T Cell Immunotherapy: Current Understanding and Future Directions

Journal of Gene Medicine
Molecular MedicineDrug DiscoveryGeneticsMolecular Biology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy